Beijing Strong BiotechnologiesInc Performance dei guadagni passati

Il passato criteri di controllo 3/6

Beijing Strong BiotechnologiesInc ha registrato una crescita degli utili a un tasso medio annuo di 17.5%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 5.9%. I ricavi sono stati in crescita a un tasso medio annuo di 16.5%. Il ritorno sul capitale proprio di Beijing Strong BiotechnologiesInc è 13.3% e ha margini netti di 30.1%.

Informazioni chiave

17.5%

Tasso di crescita degli utili

14.6%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	11.3%
Tasso di crescita dei ricavi	16.5%
Rendimento del capitale proprio	13.3%
Margine netto	30.1%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Beijing Strong BiotechnologiesInc guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

XSEC:300406 Ricavi, spese e utili (CNY Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	1,745	526	489	182
30 Jun 24	1,747	533	477	175
31 Mar 24	1,762	533	501	170
31 Dec 23	1,742	524	499	163
30 Sep 23	1,622	491	466	142
30 Jun 23	1,615	468	493	147
31 Mar 23	1,512	402	475	142
31 Dec 22	1,511	389	475	137
30 Sep 22	1,504	364	480	145
30 Jun 22	1,504	347	486	136
31 Mar 22	1,598	392	485	133
01 Jan 22	1,599	406	463	127
30 Sep 21	1,539	335	488	111
30 Jun 21	1,391	299	408	100
31 Mar 21	1,109	212	321	88
31 Dec 20	848	112	272	79
30 Sep 20	797	202	177	77
30 Jun 20	752	234	137	72
31 Mar 20	781	284	137	69
31 Dec 19	841	332	136	70
30 Sep 19	813	324	131	66
30 Jun 19	787	318	132	65
31 Mar 19	783	303	132	63
31 Dec 18	774	301	131	61
30 Sep 18	755	285	133	61
30 Jun 18	748	279	104	84
31 Mar 18	718	280	109	69
31 Dec 17	694	273	121	54
30 Sep 17	657	266	129	37
30 Jun 17	660	259	161	0
31 Mar 17	658	259	160	0
31 Dec 16	667	272	150	0
30 Sep 16	646	266	142	0
30 Jun 16	595	259	134	0
31 Mar 16	590	255	126	0
31 Dec 15	566	245	124	0
30 Sep 15	548	222	126	0
30 Jun 15	543	218	127	0
31 Mar 15	524	218	120	0
31 Dec 14	508	211	119	0
30 Sep 14	480	205	107	0
31 Dec 13	445	181	91	0

Guadagni di qualità: 300406 ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di 300406 (30.1%) sono inferiori rispetto allo scorso anno (30.3%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di 300406 sono cresciuti del 17.5% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di 300406 nell'ultimo anno ( 7.1% ) è inferiore alla media quinquennale ( 17.5% all'anno).

Guadagni vs Settore: La crescita degli utili 300406 nell'ultimo anno ( 7.1% ) ha superato la percentuale del settore Biotechs 0.08%.

Beijing Strong BiotechnologiesInc Performance dei guadagni passati

Il passato criteri di controllo 3/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.67 in FY 2022)

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.67 in FY 2022)

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.69 in FY 2021)

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings released: EPS: CN¥0.69 (vs CN¥0.21 in FY 2020)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Investor sentiment improved over the past week

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate